Home
News
Screeners
Insights
Sunil Healthcare
69.
00
+1.00
(+1.47%)
Market Cap
₹70.76 Cr
PE Ratio
19.60
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+1.47%
1M
+1.02%
6M
+1.02%
1Y
+1.02%
5Y
+1.02%
View Company Insights
Latest news about Sunil Healthcare
Sunil Healthcare Q1 Results: Unaudited financials for Q1FY27 published
6 days ago
Sunil Healthcare Limited filed its unaudited Q1FY27 results with Indian stock exchanges on August 15, 2026. The filing references publication in *Pioneer* but does not disclose specific financial metrics like revenue or profit in the notice itself. The disclosure complies with SEBI Listing Regulations.
Sunil Healthcare FY26 consolidated profit rises, standalone loss reported
May 31, 2026
Sunil Healthcare Schedules Board Meeting on May 29, 2026 to Approve Q4 and FY 2025-26 Audited Financial Results
May 19, 2026
Sunil Healthcare Limited Submits SEBI Compliance Certificate for FY 2025-26
Apr 16, 2026
Sunil Healthcare Limited Receives SEBI Compliance Certificate for Q4 FY26
Apr 07, 2026
More news about Sunil Healthcare
06
Feb 26
Sunil Healthcare Limited Announces Q3 FY26 Financial Results
Sunil Healthcare Limited announced its Q3 FY26 financial results showing standalone revenue of ₹2,183.73 lakhs and net profit of ₹44.30 lakhs for the quarter ended December 31, 2025. The consolidated results included foreign subsidiaries with revenue of ₹2,233.49 lakhs and net profit of ₹58.52 lakhs. For nine months, standalone revenue reached ₹6,799.69 lakhs with net profit of ₹151.82 lakhs.
05
Nov 25
Sunil Healthcare Reports Mixed Q2 FY2026 Results with Standalone Profit and Consolidated Loss
Sunil Healthcare Limited announced its Q2 FY2026 results, showing a standalone profit but consolidated loss. Standalone revenue increased to Rs. 235.76 lakhs in Q2, with a profit of Rs. 7.90 lakhs. Half-yearly standalone revenue reached Rs. 461.96 lakhs with a profit of Rs. 50.75 lakhs. However, consolidated operations reported a Q2 loss of Rs. 5.64 lakhs and a half-year loss of Rs. 18.47 lakhs. The Board approved these results on November 4, 2025, with auditors Singhi & Co. conducting a limited review.
Sunil Healthcare
69.
00
+
1.
00
(+
1.
47
%)
1 Year Returns:
+1.02%
Industry Peers
Sun Pharmaceutical
1,902.40
(-
0.
08
%)
Divis Laboratories
8,597.00
(+
0.
32
%)
Torrent Pharmaceuticals
4,896.50
(-
2.
17
%)
Cipla
1,432.20
(-
0.
40
%)
Zydus Life Science
1,120.00
(+
1.
11
%)
Lupin
2,201.80
(+
0.
01
%)
Mankind Pharma
2,384.00
(-
0.
04
%)
Dr Reddys Laboratories
1,174.70
(-
0.
45
%)
Laurus Labs
1,802.00
(-
1.
26
%)
Aurobindo Pharma
1,621.30
(+
0.
83
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar